CJC-1295
CJC-1295 (with and without DAC)
A GHRH analogue that extends the half-life of growth hormone-releasing hormone, typically combined with Ipamorelin.
CJC-1295 is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It comes in two forms: with DAC (Drug Affinity Complex), which extends the half-life to approximately 8 days via albumin binding, and without DAC (Modified GRF 1-29), which has a half-life of ~30 minutes.
The without-DAC version is generally considered more physiologically appropriate for producing pulsatile GH release that mimics natural patterns.
What research shows
- Sustained elevation of GH and IGF-1 in human studies (with DAC)
- Pulsatile GH release when used without DAC alongside a GHRP
- Improved body composition in small human trials
- Synergistic GH release when paired with Ipamorelin
What remains unknown
- Long-term safety in humans, particularly with chronic use
- Optimal protocol structure (with vs. without DAC, dosing frequency)
- Risk of GH receptor desensitization with continuous elevation
Administration basics
Common use cases
GH optimization, body composition, recovery. Almost always paired with Ipamorelin.
Half-life
~30 minutes (without DAC) / ~8 days (with DAC).
Administration
Subcutaneous injection. Without DAC typically dosed multiple times daily; with DAC once or twice weekly.
Source this compound
Looking for CJC-1295?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Clinical research with CJC-1295 with DAC used 1–2mg per injection every 1–2 weeks
- Community protocols commonly use CJC-1295 without DAC at 100–300mcg per injection paired with ipamorelin
Administration routes studied
Typical protocol duration
Studies have run from 6 weeks to several months. Community protocols commonly report 3–6 month cycles.
Common stacking protocols
- CJC-1295 + Ipamorelin — the standard GH peptide combination; GHRH analogue paired with a GHRP for synergistic GH release
- CJC-1295 + BPC-157 or TB-500 — combined in injury recovery and healing protocols
Contraindications & combinations to avoid
- Active cancer or personal/family history of certain cancers — GH elevation may be a concern
- Diabetes — GH peptides can affect insulin sensitivity
- Should not be combined with other GHRH analogues such as sermorelin — redundant mechanism
- Pituitary disorders — consult an endocrinologist before use
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with CJC-1295 and what to avoid.
Track your CJC-1295 protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the CJC-1295 page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.